Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets

by

in

OSAKA, Japan, Feb. 20, 2024 /PRNewswire/ — Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; “Ono”) today announced that it has entered into a research collaboration agreement with InveniAI® LLC (Guilford, Connecticut, USA; President and CEO: Krishnan Nandabalan; “InveniAI”), to identify novel therapeutic targets by leveraging cutting-edge InveniAI’s artificial intelligence (AI) and machine learning (ML).


Full story available on Benzinga.com


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *